OTC and metabolic dysfunction-associated steatohepatitis: Additionally, there was a downregulation in OTC-1 in bland steatosis (0.28 fold [CI95% 0.08–0.48]) vs. healthy controls (onefold [CI95% 0.84–1.18]) (p < 0.0001), as well as in NASH-fibrosis patients when also compared to healthy individuals (0.50 fold [CI95% 0.06–0.94]) (p = 0.01) (Fig. 1B).